Biocryst Pharmaceuticals buy JPMorgan Chase & Co.
Start price
20.11.23
/
50%
€4.86
Target price
20.11.24
€9.15
Performance (%)
44.15%
End price
21.11.24
€7.00
Summary
This prediction ended on 21.11.24 with a price of €7.00. The BUY prediction by JPMorgan_Chase___Co_ for Biocryst Pharmaceuticals saw massive gains of 44.15%. JPMorgan_Chase___Co_ has a follow-up prediction for Biocryst Pharmaceuticals where he still thinks Biocryst Pharmaceuticals is a Buy. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Biocryst Pharmaceuticals | -7.413% | -7.413% | -14.962% |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $10.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
In the thread Trading Biocryst Pharmaceuticals
Die von JPMorgan_Chase___Co_ gewählte maximale Laufzeit wurde überschritten
Current prediction by JPMorgan_Chase___Co_ for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€9.37
06.05.25
06.05.25
€11.51
06.05.26
06.05.26
-33.55%
18.12.25
18.12.25
